Risk and Protective Factors for Leprosy Development Determined by Epidemiological Surveillance of Household Contacts
- 1 January 2008
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 15 (1) , 101-105
- https://doi.org/10.1128/cvi.00372-07
Abstract
Household contacts of leprosy patients are the group with the highest risk of developing the disease, and although many risk or prevention factors have been identified, they have not been employed in leprosy-monitoring programs. This investigation aimed to establish the relative risks or the preventive effects of the presence of BCG vaccination, the Mitsuda test, and the ML-Flow assay. Household contacts (1,396) were monitored for a 5-year period. Twenty-eight contacts (2%) developed leprosy and had their clinical and operational classifications established. All immunological tests were performed, and intradermal BCG vaccination was given after the BCG scar count. Of the affected contacts, 75% developed the disease in the first year, and 71.4% were classified as having paucibacillary forms. Contacts of lepromatous leprosy patients presented a 3.8-fold-higher risk of developing leprosy. BCG vaccination and the Mitsuda test showed a protective effect against leprosy of 0.27 (at least one scar) and 0.16 (>7 mm), respectively, and the positive ML-Flow test indicated a relative risk approximately sixfold higher for occurrence of the disease. All unfavorable combinations of two and three assays generated significant risk values that ranged from 5.76 to 24.47, with the highest risk given by the combination of no BCG scar, negative Mitsuda test, and positive ML-Flow test. We suggest that the BCG vaccination may be given to stimulate Mitsuda test positivity, reducing the patient's risk of developing multibacillary forms. The high significance of these tests may have a great impact on programs to monitor contacts and should be used to improve early detection and treatment.Keywords
This publication has 19 references indexed in Scilit:
- Protective effect of bacillus Calmette Guιrin (BCG) vaccine in the prevention of leprosy: A meta-analysisIndian Journal of Dermatology, Venereology and Leprology, 2007
- ML0405 and ML2331 Are Antigens ofMycobacterium lepraewith Potential for Diagnosis of LeprosyClinical and Vaccine Immunology, 2006
- Identification of Specific Proteins and Peptides in Mycobacterium leprae Suitable for the Selective Diagnosis of LeprosyThe Journal of Immunology, 2005
- Comparative Analysis of B- and T-Cell Epitopes ofMycobacterium lepraeandMycobacterium tuberculosisCulture Filtrate Protein 10Infection and Immunity, 2004
- Simple and Fast Lateral Flow Test for Classification of Leprosy Patients and Identification of Contacts with High Risk of Developing LeprosyJournal of Clinical Microbiology, 2003
- Seroprevalence rates of antibodies to phenolic glycolipid-I among school children as an indicator of leprosy endemicity.1999
- Household and Dwelling Contact as Risk Factors for Leprosy in Northern MalawiAmerican Journal of Epidemiology, 1997
- Immunoprophylactic trial with combined Mycobacterium Leprae/BCG vaccine against leprosy: preliminary resultsThe Lancet, 1992
- BCG vaccination of children against leprosy: nine-year findings of the controlled WHO trial in Burma.1974
- BCG vaccination of children against leprosy: seven-year findings of the controlled WHO trial in Burma.1973